King's College London

Research portal

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision

Research output: Contribution to journalReview article

Standard

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. / de Blank, Peter M.K.; Fisher, Michael J.; Liu, Grant T.; Gutmann, David H.; Listernick, Robert; Ferner, Rosalie E.; Avery, Robert A.

In: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, Vol. 37, 01.09.2017, p. S23-S32.

Research output: Contribution to journalReview article

Harvard

de Blank, PMK, Fisher, MJ, Liu, GT, Gutmann, DH, Listernick, R, Ferner, RE & Avery, RA 2017, 'Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision', Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, vol. 37, pp. S23-S32. https://doi.org/10.1097/WNO.0000000000000550

APA

de Blank, P. M. K., Fisher, M. J., Liu, G. T., Gutmann, D. H., Listernick, R., Ferner, R. E., & Avery, R. A. (2017). Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 37, S23-S32. https://doi.org/10.1097/WNO.0000000000000550

Vancouver

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE et al. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2017 Sep 1;37:S23-S32. https://doi.org/10.1097/WNO.0000000000000550

Author

de Blank, Peter M.K. ; Fisher, Michael J. ; Liu, Grant T. ; Gutmann, David H. ; Listernick, Robert ; Ferner, Rosalie E. ; Avery, Robert A. / Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. In: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2017 ; Vol. 37. pp. S23-S32.

Bibtex Download

@article{2a6f4573630a476fa0fbde1580fe4ecc,
title = "Optic Pathway Gliomas in Neurofibromatosis Type 1:: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision",
abstract = "Optic pathway gliomas (OPGs) occur in 15%-20% of children with neurofibromatosis type 1 (NF1), leading to visual deficits in fewer than half of these individuals. The goal of chemotherapy is to preserve vision, but vision loss in NF1-associated OPG can be unpredictable. Determining which child would benefit from chemotherapy and, equally important, which child is better observed without treatment can be difficult. Unfortunately, despite frequent imaging and ophthalmologic evaluations, some children experience progressive vision loss before treatment. Indications for chemotherapy usually are based on a comprehensive, quantitative assessment of vision, but reliable vision evaluation can be challenging in young children with NF1-OPG. The ability to identify and predict impending vision loss could potentially improve management decisions and visual outcomes. To address this challenge, ophthalmologic, electrophysiologic, and imaging biomarkers of vision in NF1-OPG have been proposed. We review current recommendations for the surveillance of children at risk for NF1-OPG, outline guidelines for initiating therapy, and describe the utility of proposed biomarkers for vision.",
author = "{de Blank}, {Peter M.K.} and Fisher, {Michael J.} and Liu, {Grant T.} and Gutmann, {David H.} and Robert Listernick and Ferner, {Rosalie E.} and Avery, {Robert A.}",
year = "2017",
month = sep,
day = "1",
doi = "10.1097/WNO.0000000000000550",
language = "English",
volume = "37",
pages = "S23--S32",
journal = "Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society",
issn = "1536-5166",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Optic Pathway Gliomas in Neurofibromatosis Type 1:

T2 - An Update: Surveillance, Treatment Indications, and Biomarkers of Vision

AU - de Blank, Peter M.K.

AU - Fisher, Michael J.

AU - Liu, Grant T.

AU - Gutmann, David H.

AU - Listernick, Robert

AU - Ferner, Rosalie E.

AU - Avery, Robert A.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Optic pathway gliomas (OPGs) occur in 15%-20% of children with neurofibromatosis type 1 (NF1), leading to visual deficits in fewer than half of these individuals. The goal of chemotherapy is to preserve vision, but vision loss in NF1-associated OPG can be unpredictable. Determining which child would benefit from chemotherapy and, equally important, which child is better observed without treatment can be difficult. Unfortunately, despite frequent imaging and ophthalmologic evaluations, some children experience progressive vision loss before treatment. Indications for chemotherapy usually are based on a comprehensive, quantitative assessment of vision, but reliable vision evaluation can be challenging in young children with NF1-OPG. The ability to identify and predict impending vision loss could potentially improve management decisions and visual outcomes. To address this challenge, ophthalmologic, electrophysiologic, and imaging biomarkers of vision in NF1-OPG have been proposed. We review current recommendations for the surveillance of children at risk for NF1-OPG, outline guidelines for initiating therapy, and describe the utility of proposed biomarkers for vision.

AB - Optic pathway gliomas (OPGs) occur in 15%-20% of children with neurofibromatosis type 1 (NF1), leading to visual deficits in fewer than half of these individuals. The goal of chemotherapy is to preserve vision, but vision loss in NF1-associated OPG can be unpredictable. Determining which child would benefit from chemotherapy and, equally important, which child is better observed without treatment can be difficult. Unfortunately, despite frequent imaging and ophthalmologic evaluations, some children experience progressive vision loss before treatment. Indications for chemotherapy usually are based on a comprehensive, quantitative assessment of vision, but reliable vision evaluation can be challenging in young children with NF1-OPG. The ability to identify and predict impending vision loss could potentially improve management decisions and visual outcomes. To address this challenge, ophthalmologic, electrophysiologic, and imaging biomarkers of vision in NF1-OPG have been proposed. We review current recommendations for the surveillance of children at risk for NF1-OPG, outline guidelines for initiating therapy, and describe the utility of proposed biomarkers for vision.

UR - http://www.scopus.com/inward/record.url?scp=85032615712&partnerID=8YFLogxK

U2 - 10.1097/WNO.0000000000000550

DO - 10.1097/WNO.0000000000000550

M3 - Review article

C2 - 28806346

AN - SCOPUS:85032615712

VL - 37

SP - S23-S32

JO - Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

JF - Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

SN - 1536-5166

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454